Content area
Full text
Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities. The allowance approved 40 claims in connection with technology that enables an entirely new system and method of airway and vessel intervention.
"Pulmonary disease is a global epidemic," said Sanovas CEO and co-founder Larry Gerrans. "We are leading the efforts to combat the disease and...